Myelodysplastic syndrome therapeutics pipeline is expected to grow primarily due to the increasing prevalence of the disease as a result of increasing exposure of general population to chemicals and radiation. Some of the main factors driving the pipeline for myelodysplastic syndrome include rising older population, increasing exposure of heavy metals, smoking, tobacco consumption, low market penetration since a limited number of companies are making an analog of marketed drugs and increasing health awareness among people. According to the American Cancer Society, around 13,000 new cases of myelodysplastic syndrome are diagnosed each year in the U.S. It usually occurs in people with age of 65 years and above and is more prevalent among males as compared with females.
Myelodysplastic syndrome is a group of disorders in which unhealthy blood cells are formed with poor function. The cause of myelodysplastic syndrome is still unknown but it is assumed that myelodysplastic syndrome is caused by exposure to chemicals and radiations. The risk factors of myelodysplastic syndrome include smoking, environmental exposures, other cancers and genetic syndromes. The symptoms of myelodysplastic syndrome are anaemia, shortness of breath, unusual bleeding, petechiae and frequent infections. The symptoms of myelodysplastic syndrome usually occur in late stages, which results in late diagnosis of the disease. There are several types of myelodysplastic syndrome including refractory cytopenia with unilineage dysplasia, refractory anemia with ringed sideroblasts, refractory cytopenia with multilineage dysplasia, refractory anemia with excess blasts and myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality. The diagnosis of myelodysplastic syndrome is done by blood tests and bone marrow testing. Myelodysplastic syndrome is treated by blood transfusions, medications and bone marrow stem cell transplant. Also, changing lifestyle habits can help in improving the life of patient.
Request for table of Content at: https://www.psmarketresearch.com/market-analysis/myelodysplastic-syndrome-therapeutics-pipeline-analysis/toc-sample
Some of the companies having a pipeline of myelodysplastic syndrome therapeutics include Celgene Corporation, Janssen Research & Development, LLC, Onconova Therapeutics, Inc., Astex Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., GlaxoSmithKline Plc, AbbVie, Inc., Genentech, Inc., Kura Oncology, Inc., Boehringer Ingelheim GmbH, Novartis AG, Syros Pharmaceuticals, Inc., Millennium Pharmaceuticals, Inc., Acceleron Pharma, Inc., Pfizer Inc.
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY – 10016
Toll-free: +1-888-778-7886 (USA/Canada)